Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

Grom A. A. , Ilowite N. T. , Pascual V., Brunner H. I. , Martini A., Lovell D., ...Daha Fazla

ARTHRITIS & RHEUMATOLOGY, cilt.68, sa.1, ss.218-228, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 68 Konu: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1002/art.39407
  • Sayfa Sayıları: ss.218-228


ObjectiveIn pivotal trials, canakinumab has been shown to be effective in the treatment of systemic juvenile idiopathic arthritis (JIA), but reported adverse events have included macrophage activation syndrome (MAS). This study was undertaken to assess the impact of canakinumab on MAS incidence.